Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
Status:
Withdrawn
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see if adding the experimental medication, axitinib, to
usual treatment with pembrolizumab will work better than pembrolizumab alone. The study team
will look at overall safety and side effects of the combination of axitinib and pembrolizumab
to see how well it is tolerated. Researchers will also want to take some research blood
samples to explore what effects the combination of treatment has on participants' cells and
immune system and to see if there are things in participants' blood that can predict a
response or resistance to the combined treatment.